Newly identified strains of Chlamydia trachomatis could produce new diseasesNovember 16, 2006A new study led by a scientist at Children's Hospital Oakland Research Institute (CHORI) is the first to conclude that Chlamydia trachomatis is evolving at a rate faster than scientists first thought or imagined. Chlamydia trachomatis is a bacterium that is the leading cause of sexually transmitted diseases and the second leading cause of blindness worldwide. Scientists believe the bacterium is evolving through a process called recombination where genes from one or more strains combine to create new strains and - theoretically - new diseases. The study is featured in the November issue of Genome Research and was led by Dr. Deborah Dean MD, MPH, senior scientist at Children's Hospital Oakland Research Institute (CHORI). Her research suggests that since Chlamydia trachomatis evolves through recombination where one or more strains combine, the traditional method of studying a single gene to track the transmission of the bacterium is wrong. "What we found is an organism that not only evolves rapidly, but in ways that we thought were rare. We also discovered that this organism can customize its attack," said Dr. Dean. "Consequently, the constant flux of the bacterium could serve as a gateway for new emerging diseases, but more research needs to be conducted to understand if and how this is happening." 600 million people are infected across the globe with Chlamydia trachomatis and 8 million are already blind or severely visually impaired. In some parts of third-world countries, more than 90% of the population is infected. Chlamydia trachomatis has a variety of strains; different strains are responsible for different diseases. Some strains cause sexually transmitted diseases while others cause eye infections. Blinding trachoma is caused by repeated eye infections that cause scarring, which result in the eyelashes turning in-wards. Bacterial infection develops as the eyelashes scratch the surface of the eye, which eventually heals by scarring, resulting in blindness. Previously, the organism was identified using a single gene, ompA, and the protein encoded by that gene, MOMP. In this study, the clinical strains, which are samples of Chlamydia trachomatis currently responsible for human disease today, were compared to standard reference strains that have been laboratory adapted over the last few decades. By studying multiple strains, the researchers discovered that the strains that were identified as the same strain were actually different. The next step will be to study clinical strains in comparison with laboratory reference strains to decipher exactly how different strains cause disease and whether new diseases are emerging as a result of the emergence of new strains. "Large-scale comparative genomics will be necessary to understand the precise mechanisms underlying Chlamydia trachomatis recombination and how other species of chamydiae may evolve and transfer from animals to humans." Children's Hospital & Research Center at Oakland |
|||||||||||||||||||||
| Related Chlamydia Trachomatis Current Events and Chlamydia Trachomatis News Articles New chlamydia test offers rapid, pain-free test for men A new urine test developed with funding from the Wellcome Trust will allow doctors to diagnose Chlamydia infection in men within the hour, improving the ability to successfully treat the infection on the spot and prevent re-transmission. Chlamydia that avoids diagnosis New sequencing and analysis of six strains Chlamydia will result in improved diagnosis of the sexually transmitted infection. Researchers design unique method to induce immunity to certain STDs Chlamydia trachomatis is the most common bacterial agent of sexually transmitted disease, accounting for more than a million reported infections in the United States each year. Multiple species of bacteria may cause trachoma: Implications for treatment In a study published in this week's PLoS Medicine, researchers have found that more than one species of bacteria may be causing the infectious eye disease trachoma. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia Scientists at Children's Hospital of Pittsburgh of UPMC have identified a potential target for the development of a vaccine against Chlamydia trachomatis, the most prevalent sexually transmitted bacterial infection in the world. HPV vaccine does not appear to be effective for treating pre-existing HPV infection For women with human papillomavirus (HPV) infection, use of the HPV-16/18 vaccine will not accelerate reduction of the virus and should not be used to treat the infection, according to a study in the August 15 issue of JAMA. Proactive chlamydia screening is not good value for money Proactive chlamydia screening for young adults is an expensive intervention that probably does not represent good value for money, concludes a study published on bmj.com today. Opportunistic chlamydia screening 'not underpinned by sound evidence The value of opportunistic chlamydia screening is called into question in this week's BMJ. University and health science center in San Antonio collaborate to find chlamydia vaccine It's the most common bacteria-related sexually transmitted disease in the United States, so researchers at The University of Texas at San Antonio's South Texas Center for Emerging Infectious Diseases (STCEID) and The University of Texas at San Antonio Health Science Center have partnered to discover a vaccine that will prevent Chlamydia. Use of antibiotic to treat infectious eye disease trachoma may increase risk for reinfection Use of the antibiotic azithromycin to treat trachoma in Vietnam resulted in an increase in the risk of re-infections. More Chlamydia Trachomatis Current Events and Chlamydia Trachomatis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||